Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
US8993628B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993628-B2 |
| Application number | US-3605008-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 22, 2008 |
| Priority date | Feb 23, 2007 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
LXR nuclear receptor agonists have been previously shown to increase cholesterol efflux, raise plasma HDL cholesterol, stimulate cholesterol excretion, and reduce atherosclerotic lesions. However, these agonists have also been associated with the unwanted side effect of hypertriglyeridemia. This hypertriglyeridemia appears to be mediated by the LXRα subtype rather than LXRβ, which suggests that LXRβ-selective agonists are attractive candidates for modulation of human lipid metabolism. The present application provides novel LXRβ-selective ligands that preferably modulate LXRβ over LXRα. These ligands may be used to treat a variety of diseases associated with LXR, such as for example lipid metabolism disorders, atherosclerosis, Alzheimer disease, and inflammation.
First claim
Opening claim text (preview).
What is claimed is: 1. An LXRβ-selective ligand having the formula: wherein R is 2. A pharmaceutical composition comprising a therapeutically effective amount of an LXRβ-selective ligand and a pharmaceutically acceptable carrier, wherein the LXRβ-s…
Assignees
Inventors
Classifications
- A61K31/195Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993628B2 cover?
- LXR nuclear receptor agonists have been previously shown to increase cholesterol efflux, raise plasma HDL cholesterol, stimulate cholesterol excretion, and reduce atherosclerotic lesions. However, these agonists have also been associated with the unwanted side effect of hypertriglyeridemia. This hypertriglyeridemia appears to be mediated by the LXRα subtype rather than LXRβ, which suggests that…
- Who is the assignee on this patent?
- Forman Barry, Yu Donna, Hope City
- What technology area does this patent fall under?
- Primary CPC classification A61K31/195. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).